Glutamate receptors as therapeutic targets for Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 6, 2009, Pages 475-491

  Johnson, Kari A ^a   Conn, P Jeffrey ^a   Niswender, Colleen M ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

AMPA receptor; Basal ganglia; Levodopa induced dyskinesia; Metabotropic glutamate receptor; Neurodegeneration; NMDA receptor; Parkinson's disease

Indexed keywords

(2,2',3') 2 (2',3' DICARBOXYCYCLOPROPYL)GLYCINE; (3 ETHYL 2 METHYL QUINOLIN 6 YL) (4 METHOXY CYCLOHEXYL) METHANONE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; 7 CHLOROKYNURENIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADX 48621; AMANTADINE; AMPA RECEPTOR; ANTIPARKINSON AGENT; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DEXTRORPHAN; DIZOCILPINE; GLUTAMATE RECEPTOR; IFENPRODIL; LEVODOPA; MRZ 2 570; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERAMEXANE; RACLOPRIDE; REMACEMIDE; SDZ 220581; TALAMPANEL; TOPIRAMATE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BASAL GANGLION; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; HUMAN; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MODELS, BIOLOGICAL; NEURAL PATHWAYS; PARKINSON DISEASE; RECEPTORS, GLUTAMATE;

EID: 75849152052     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789824606     Document Type: Review

References (221)

1. Lang, A.E.; Lozano, A.M. Parkinson's disease. first of two parts. N. Engl. J. Med., 1998, 339(15), 1044-1053.
2. Moghal, S.; Rajput, A.H.; D'Arcy, C.; Rajput, R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology, 1994, 13(4), 175-178.
3. Zhang, Z.X.; Roman, G.C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology, 1993, 12(4), 195-208.
4. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79(4), 368-376.
5. Blackett, H.; Walker, R.; Wood, B. Urinary dysfunction in Parkinson's disease: a review. Parkinsonism Relat. Disord., 2009, 15(2), 81-87.
6. DeLong, M.R.; Wichmann, T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol., 2007, 64(1), 20-24.
7. Chen, J.J.; Swope, D.M. Pharmacotherapy for Parkinson's disease. Pharmacotherapy, 2007, 27(12 Pt 2), 161S-173S.
8. Stacy, M.; Galbreath, A. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clin. Neuropharmacol., 2008, 31(1), 51-56.
9. Betarbet, R.; Sherer, T.B.; Greenamyre, J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol., 2005, 191(Suppl 1), S17-S27.
10. Gandhi, S.; Wood, N.W. Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet., 2005, 14(Spec No. 2), 2749-2755.
11. Olanow, C.W. The pathogenesis of cell death in Parkinson's disease. Mov. Disord., 2007, 22(S17), S335-S342.
12. Przedborski, S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat. Disord., 2005, 11(Suppl 1), S3-S7.
13. Wichmann, T.; DeLong, M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol., 1996, 6(6), 751-758.
14. Bergman, H.; Wichmann, T.; Karmon, B.; DeLong, M.R. The primate subthalamic nucleus. II: neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol., 1994, 72(2), 507-520.
15. Liu, X.; Ford-Dunn, H.L.; Hayward, G.N.; Nandi, D.; Miall, R.C.; Aziz, T.Z.; Stein, J.F. The oscillatory activity in the Parkinsonian subthalamic nucleus investigated using the macro-electrodes for deep brain stimulation. Clin. Neurophysiol., 2002, 113(11), 1667-1672.
16. Ni, Z.; Bouali-Benazzouz, R.; Gao, D.; Benabid, A.L.; Benazzouz, A. Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat. Synapse, 2001, 40(2), 145-153.
17. Ni, Z.G.; Bouali-Benazzouz, R.; Gao, D.M.; Benabid, A.L.; Benazzouz, A. Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHD-A-induced dopamine depletion in rats. Brain Res., 2001, 899(1-2), 142-147.
18. Vila, M.; Perier, C.; Feger, J.; Yelnik, J.; Faucheux, B.; Ruberg, M.; Raisman-Vozari, R.; Agid, Y.; Hirsch, E.C. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur. J. Neurosci., 2000, 12(1), 337-344.
19. Carvalho, G.A.; Nikkhah, G. Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp. Neurol., 2001, 171(2), 405-417.
20. Smith, Y.; Bevan, M.D.; Shink, E.; Bolam, J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience, 1998, 86(2), 353-387.
21. Parent, A.; Levesque, M.; Parent, M. A re-evaluation of the current model of the basal ganglia. Parkinsonism Relat. Disord., 2001, 7(3), 193-198.
22. Yelnik, J. Functional anatomy of the basal ganglia. Mov. Disord., 2002, 17(Suppl 3), S15-S21.
23. Smith, Y.; Kieval, J.Z. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci., 2000, 23(10 Suppl), S28-S33.
24. Blandini, F.; Nappi, G.; Tassorelli, C.; Martignoni, E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol., 2000, 62(1), 63-88.
25. Heimer, G.; Rivlin, M.; Israel, Z.; Bergman, H. Synchronizing activity of basal ganglia and pathophysiology of Parkinson's disease. J. Neural Transm. Suppl., 2006, 70, 17-20.
26. Leblois, A.; Meissner, W.; Bezard, E.; Bioulac, B.; Gross, C.E.; Boraud, T. Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. Eur. J. Neurosci., 2006, 24(4), 1201-1208.
27. Leblois, A.; Boraud, T.; Meissner, W.; Bergman, H.; Hansel, D. Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia. J. Neurosci., 2006, 26(13), 3567-3583.
28. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51(1), 7-61.
29. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci., 2000, 20(21), 7871-7879.
30. Gotz, T.; Kraushaar, U.; Geiger, J.; Lubke, J.; Berger, T.; Jonas, P. Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. J. Neurosci., 1997, 17(1), 204-215.
31. Marino, M.J.; Valenti, O.; Conn, P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging, 2003, 20(5), 377-397.
32. Pisani, A.; Calabresi, P.; Centonze, D.; Bernardi, G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br. J. Pharmacol., 1997, 120(6), 1007-10014.
33. Waxman, E.A.; Lynch, D.R. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist, 2005, 11(1), 37-49.
34. Conn, P.J.; Battaglia, G.; Marino, M.J.; Nicoletti, F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci., 2005, 6(10), 787-798.
35. Orth, M.; Tabrizi, S.J. Models of Parkinson's disease. Mov. Disord., 2003, 18(7), 729-737.
36. Terzioglu, M.; Galter, D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J., 2008, 275(7), 1384-1391.
37. Betarbet, R.; Sherer, T.B.; Greenamyre, J.T. Animal models of Parkinson's disease. Bioessays, 2002, 24(4), 308-318.
38. Gerlach, M.; Riederer, P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm., 1996, 103(8-9), 987-1041.
39. Hornykiewicz, O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev., 1966, 18(2), 925-964.
40. Schober, A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res., 2004, 318(1), 215-224.
41. Javitch, J.A.; D'Amato, R.J.; Strittmatter, S.M.; Snyder, S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 - tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA, 1985, 82(7), 2173-2177.
42. Tipton, K.F.; Singer, T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem., 1993, 61(4), 1191-1206.
43. Simola, N.; Morelli, M.; Carta, A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res., 2007, 11(3-4), 151-167.
44. Deumens, R.; Blokland, A.; Prickaerts, J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol., 2002, 175(2), 303-317.
45. Lundblad, M.; Andersson, M.; Winkler, C.; Kirik, D.; Wierup, N.; Cenci, M. A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci., 2002, 15(1), 120-132.
46. Amalric, M.; Moukhles, H.; Nieoullon, A.; Daszuta, A. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur. J. Neurosci., 1995, 7(5), 972-980.
47. Walter, B.L.; Vitek, J.L. Surgical treatment for Parkinson's disease. Lancet Neurol., 2004, 3(12), 719-728.
48. Wichmann, T.; Delong, M.R. Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron, 2006, 52(1), 197-204.
49. Lozano, A.M.; Eltahawy, H. How does DBS work? Suppl. Clin. Neurophysiol., 2004, 57, 733-736.
50. Greenamyre, J.T.; O'Brien, C.F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol., 1991, 48(9), 977-981.
51. Ossowska, K. The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect., 1994, 8(1-2), 39-71.
52. Schmidt, W.J.; Kretschmer, B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev., 1997, 21(4), 381-392.
53. Bubser, M.; Zadow, B.; Kronthaler, U.O.; Felsheim, U.; Ruckert, N.G.; Schmidt, W.J. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism. Naunyn. Schmiedebergs Arch. Pharmacol., 1997, 355(6), 767-773.
54. Karcz-Kubicha, M.; Lorenz, B.; Danysz, W. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease-comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology, 1999, 38(1), 109-119.
55. Kaur, S.; Ozer, H.; Starr, M. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur. J. Pharmacol., 1997, 332(2), 153-160.
56. Konieczny, J.; Ossowska, K.; Schulze, G.; Coper, H.; Wolfarth, S. L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl), 1999, 143(3), 235-243.
57. Kretschmer, B.D.; Winterscheid, B.; Danysz, W.; Schmidt, W.J. Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J. Neural Transm. Gen. Sect., 1994, 95(2), 123-136.
58. Kretschmer, B.D.; Zadow, B.; Volz, T.L.; Volz, L.; Schmidt, W.J. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J. Neural Transm. Gen. Sect., 1992, 87(1), 23-35.
59. McAllister, K.H. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur. J. Pharmacol., 1996, 314(3), 307-311.
60. Mehta, A.K.; Ticku, M.K. Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci., 1990, 46(1), 37-42.
61. Moore, N.A.; Blackman, A.; Awere, S.; Leander, J.D. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur. J. Pharmacol., 1993, 237(1), 1-7.
62. Papa, S.M.; Engber, T.M.; Boldry, R.C.; Chase, T.N. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur. J. Pharmacol., 1993, 232(2-3), 247-253.
63. Schmidt, W.J.; Bubser, M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav., 1989, 32(3), 621-623.
64. Steece-Collier, K.; Chambers, L.K.; Jaw-Tsai, S.S.; Menniti, F.S.; Greenamyre, J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp. Neurol., 2000, 163(1), 239-243.
65. Carlsson, M.; Carlsson, A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm., 1989, 77(1), 65-71.
66. Carlsson, M.; Carlsson, A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm., 1989, 75(3), 221-226.
67. Dutra, R.C.; Andreazza, A.P.; Andreatini, R.; Tufik, S.; Vital, M.A. Behavioral effects of MK-801 on reserpine-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(3), 487-495.
68. Gossel, M.; Schmidt, W.J.; Loscher, W.; Zajaczkowski, W.; Danysz, W. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J. Neural Transm. Park. Dis. Dement. Sect., 1995, 10(1), 27-39.
69. Kaur, S.; Starr, M.S. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol., 1995, 280(2), 159-166.
70. Klockgether, T.; Turski, L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol., 1990, 28(4), 539-546.
71. Nash, J.E.; Hill, M.P.; Brotchie, J.M. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol., 1999, 155(1), 42-48.
72. Ossowska, K.; Lorenc-Koci, E.; Wolfarth, S. Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. J. Neural. Transm. Park. Dis. Dement. Sect., 1994, 7(2), 143-152.
73. Schwarz, M.; Nolden-Koch, M.; Purr, J.; Pergande, G.; Block, F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J. Neural Transm., 1996, 103(5), 581-590.
74. Skuza, G.; Rogoz, Z.; Quack, G.; Danysz, W. Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. J. Neural Transm. Gen. Sect., 1994, 98(1), 57-67.
75. Stauch Slusher, B.; Rissolo, K.C.; Jackson, P.F.; Pullan, L.M. Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. J. Neural. Transm. Gen. Sect., 1994, 97(3), 175-185.
76. Graham, W.C.; Robertson, R.G.; Sambrook, M.A.; Crossman, A.R. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci., 1990, 47(18), PL91-PL97.
77. Kelsey, J.E.; Mague, S.D.; Pijanowski, R. S.; Harris, R. C.; Kleckner, N. W.; Matthews, R. T. NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmaco-logy (Berl.), 2004, 175(2), 179-188.
78. Klockgether, T.; Wullner, U.; Steinbach, J. P.; Petersen, V.; Turski, L.; Loschmann, P. A. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur. J. Pharmacol., 1996, 301(1-3), 67-73.
79. Loschmann, P.A.; De Groote, C.; Smith, L.; Wullner, U.; Fischer, G.; Kemp, J.A.; Jenner, P.; Klockgether, T. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol., 2004, 187(1), 86-93.
80. Loschmann, P.A.; Wullner, U.; Heneka, M.T.; Schulz, J.B.; Kunow, M.; Wachtel, H.; Klockgether, T. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse, 1997, 26(4), 381-391.
81. Mitchell, I.J.; Carroll, C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci. Biobehav. Rev., 1997, 21(4), 469-475.
82. Nash, J.E.; Fox, S.H.; Henry, B.; Hill, M. P.; Peggs, D.; McGuire, S.; Maneuf, Y.; Hille, C.; Brotchie, J.M.; Crossman, A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol., 2000, 165(1), 136-142.
83. St-Pierre, J.A.; Bedard, P.J. Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine. Eur. J. Pharmacol., 1995, 272(2-3), 123-129.
84. Marti, M.; Paganini, F.; Stocchi, S.; Mela, F.; Beani, L.; Bianchi, C.; Morari, M. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J. Neurochem., 2003, 84(4), 792-802.
85. Blanchet, P.J.; Konitsiotis, S.; Whittemore, E.R.; Zhou, Z.L.; Woodward, R.M.; Chase, T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther., 1999, 290(3), 1034-1040.
86. Engber, T.M.; Papa, S.M.; Boldry, R.C.; Chase, T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport, 1994, 5(18), 2586-2588.
87. Greenamyre, J.T.; Eller, R.V.; Zhang, Z.; Ovadia, A.; Kurlan, R.; Gash, D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol., 1994, 35(6), 655-661.
88. Loschmann, P.A.; Lange, K.W.; Kunow, M.; Rettig, K.J.; Jahnig, P.; Honore, T.; Turski, L.; Wachtel, H.; Jenner, P.; Marsden, C.D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J. Neural. Transm. Park. Dis. Dement. Sect., 1991, 3(3), 203-213.
89. Marin, C.; Papa, S.; Engber, T.M.; Bonastre, M.; Tolosa, E.; Chase, T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res., 1996, 736(1-2), 202-205.
90. Schelkun, R.M.; Yuen, P.W.; Serpa, K.; Meltzer, L.T.; Wise, L.D.; Whittemore, E.R.; Woodward, R.M. Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements. J. Med. Chem., 2000, 43(9), 1892-1897.
91. Wright, J.L.; Gregory, T.F.; Boxer, P.A.; Meltzer, L.T.; Serpa, K.A.; Wise, L.D. Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists. Bioorg. Med. Chem. Lett., 1999, 9(19), 2815-2818.
92. Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 2007, 7(1), 39-47.
93. Jin, D.H.; Jung, Y.W.; Ko, B.H.; Moon, I.S. Immunoblot analyses on the differential distribution of NR2A and NR2B subunits in the adult rat brain. Mol. Cells, 1997, 7(6), 749-754.
94. Kosinski, C.M.; Standaert, D.G.; Counihan, T.J.; Scherzer, C.R.; Kerner, J.A.; Daggett, L.P.; Velicelebi, G.; Penney, J.B.; Young, A.B.; Landwehrmeyer, G.B. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J. Comp. Neurol., 1998, 390(1), 63-74.
95. Kuppenbender, K.D.; Standaert, D.G.; Feuerstein, T.J.; Penney, J.B.; Jr.; Young, A.B.; Landwehrmeyer, G.B. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J. Comp. Neurol., 2000, 419(4), 407-421.
96. Schito, A.M.; Pizzuti, A.; Di Maria, E.; Schenone, A.; Ratti, A.; Defferrari, R.; Bellone, E.; Mancardi, G.L.; Ajmar, F.; Mandich, P. mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit. Neurosci. Lett., 1997, 239(1), 49-53.
97. No authors listed. Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov. Disord., 2002, 17(Suppl 4), S13-S22.
98. Jankovic, J.; Stacy, M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs, 2007, 21(8), 677-692.
99. Kornhuber, J.; Quack, G.; Danysz, W.; Jellinger, K.; Danielczyk, W.; Gsell, W.; Riederer, P. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology, 1995, 34(7), 713-721.
100. Verhagen Metman, L.; Del Dotto, P.; van den Munckhof, P.; Fang, J.; Mouradian, M.M.; Chase, T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology, 1998, 50(5), 1323-1326.
101. Inzelberg, R.; Bonuccelli, U.; Schechtman, E.; Miniowich, A.; Strugatsky, R.; Ceravolo, R.; Logi, C.; Rossi, C.; Klein, C.; Rabey, J.M. Association between amantadine and the onset of dementia in Parkinson's disease. Mov. Disord., 2006, 21(9), 1375-1379.
102. Danysz, W.; Parsons, C.G.; Kornhuber, J.; Schmidt, W.J.; Quack, G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev., 1997, 21(4), 455-468.
103. Paquette, M.A.; Brudney, E.G.; Putterman, D.B.; Meshul, C.K.; Johnson, S.W.; Berger, S.P. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport, 2008, 19(1), 111-115.
104. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch. Neurol., 2001, 58(10), 1660-1668.
105. Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology, 2000, 54(8), 1583-1588.
106. Clarke, C.E.; Cooper, J.A.; Holdich, T.A. A randomized, doubleblind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin. Neuropharmacol., 2001, 24(3), 133-138.
107. Shoulson, I.; Penney, J.; McDermott, M.; Schwid, S.; Kayson, E.; Chase, T.; Fahn, S.; Greenamyre, J.T.; Lang, A.; Siderowf, A.; Pearson, N.; Harrison, M.; Rost, E.; Colcher, A.; Lloyd, M.; Matthews, M.; Pahwa, R.; McGuire, D.; Lew, M.F.; Schuman, S.; Marek, K.; Broshjeit, S.; Factor, S.; Brown, D.; Feigin, A.; Mazurkiewicz, J.; Ford, B.; Jennings, D.; Dilllon, S.; Comella, C.; Blasucci, L.; Janko, K.; Shulman, L.; Wiener, W.; Bateman-Rodriguez, D.; Carrion, A.; Suchowersky, O.; Lafontaine, A.L.; Pantella, C.; Siemers, E.; Belden, J.; Davies, R.; Lannon, M.; Grimes, D.; Gray, P.; Martin, W.; Kennedy, L.; Adler, C.; Newman, S.; Hammerstad, J.; Stone, C.; Lewitt, P.; Bardram, K.; Mistura, K.; Miyasaki, J.; Johnston, L.; Cha, J. H.; Tennis, M.; Panniset, M.; Hall, J.; Tetrud, J.; Friedlander, J.; Hauser, R.; Gauger, L.; Rodnitzky, R.; Deleo, A.; Dobson, J.; Seeberger, L.; Dingmann, C.; Tarsy, D.; Ryan, P.; Elmer, L.; Ruzicka, D.; Stacy, M.; Brewer, M.; Locke, B.; Baker, D.; Casaceli, C.; Day, D.; Florack, M.; Hodgeman, K.; Laroia, N.; Nobel, R.; Orme, C.; Rexo, L.; Rothenburgh, K.; Sulimowicz, K.; Watts, A.; Wratni, E.; Tariot, P.; Cox, C.; Leventhal, C.; Alderfer, V.; Craun, A. M.; Frey, J.; McCree, L.; McDermott, J.; Cooper, J.; Holdich, T.; Read, B. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology, 2001, 56(4), 455-462.
108. Nutt, J.G.; Gunzler, S.A.; Kirchhoff, T.; Hogarth, P.; Weaver, J.L.; Krams, M.; Jamerson, B.; Menniti, F.S.; Landen, J.W. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord., 2008, 23(13), 1860-1866.
109. Montastruc, J.L.; Rascol, O.; Senard, J.M.; Rascol, A. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1992, 55(7), 630-631.
110. Zadow, B.; Schmidt, W.J. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn. Schmiedebergs. Arch. Pharmacol., 1994, 349(1), 61-65.
111. Loschmann, P.A.; Kunow, M.; Wachtel, H. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease. J. Neural Transm. Suppl., 1992, 38, 55-64.
112. Wachtel, H.; Kunow, M.; Loschmann, P.A. NBQX (6-nitro-sulfamoyl-benzo- quinoxaline-dione) and CPP (3-carboxypiperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci. Lett., 1992, 142(2), 179-182.
113. Maj, J.; Rogoz, Z.; Skuza, G.; Kolodziejczyk, K. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. Pol. J. Pharmacol., 1995, 47(6), 501-507.
114. Klockgether, T.; Turski, L.; Honore, T.; Zhang, Z.M.; Gash, D.M.; Kurlan, R.; Greenamyre, J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol., 1991, 30(5), 717-723.
115. Brotchie, J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord., 2005, 20(8), 919-931.
116. Calon, F.; Rajput, A.H.; Hornykiewicz, O.; Bedard, P.J.; Di Paolo, T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis., 2003, 14(3), 404-416.
117. Konitsiotis, S.; Blanchet, P.J.; Verhagen, L.; Lamers, E.; Chase, T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology, 2000, 54(8), 1589-1595.
118. Silverdale, M.A.; Nicholson, S.L.; Crossman, A.R.; Brotchie, J.M. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov. Disord., 2005, 20(4), 403-409.
119. Marin, C.; Jimenez, A.; Bonastre, M.; Vila, M.; Agid, Y.; Hirsch, E.C.; Tolosa, E. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse, 2001, 42(1), 40-47.
120. Bibbiani, F.; Oh, J.D.; Kielaite, A.; Collins, M.A.; Smith, C.; Chase, T.N. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol., 2005, 196(2), 422-429.
121. Conn, P.J.; Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 205-237.
122. Pin, J.P.; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995, 34(1), 1-26.
123. Pin, J.P.; Acher, F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr. Drug Targets CNS Neurol. Disord., 2002, 1(3), 297-317.
124. Marino, M.J.; Awad-Granko, H.; Ciombor, K.J.; Conn, P.J. Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata. Neuropharmacology, 2002, 43(2), 147-159.
125. Marino, M.J.; Wittmann, M.; Bradley, S.R.; Hubert, G.W.; Smith, Y.; Conn, P.J. Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. J. Neurosci., 2001, 21(18), 7001-7012.
126. Breysse, N.; Amalric, M.; Salin, P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci., 2003, 23(23), 8302-8309.
127. Breysse, N.; Baunez, C.; Spooren, W.; Gasparini, F.; Amalric, M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci., 2002, 22(13), 5669-5678.
128. Coccurello, R.; Breysse, N.; Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology, 2004, 29(8), 1451-1461.
129. Ossowska, K.; Konieczny, J.; Wolfarth, S.; Pilc, A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology, 2005, 49(4), 447-455.
130. Ossowska, K.; Konieczny, J.; Wolfarth, S.; Wieronska, J.; Pilc, A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 2001, 41(4), 413-420.
131. Spooren, W.P.; Gasparini, F.; Bergmann, R.; Kuhn, R. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol., 2000, 406(3), 403-410.
132. Turle-Lorenzo, N.; Breysse, N.; Baunez, C.; Amalric, M. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease. Psychopharmacology (Berl.), 2005, 179(1), 117-127.
133. Kachroo, A.; Orlando, L.R.; Grandy, D.K.; Chen, J.F.; Young, A.B.; Schwarzschild, M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci., 2005, 25(45), 10414-10419.
134. Domenici, M.R.; Pepponi, R.; Martire, A.; Tebano, M.T.; Potenza, R.L.; Popoli, P. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. J. Neurochem., 2004, 90(5), 1276-1279.
135. Nishi, A.; Liu, F.; Matsuyama, S.; Hamada, M.; Higashi, H.; Nairn, A.C.; Greengard, P. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc. Natl. Acad. Sci. USA, 2003, 100(3), 1322-1327.
136. Popoli, P.; Pezzola, A.; Torvinen, M.; Reggio, R.; Pintor, A.; Scarchilli, L.; Fuxe, K.; Ferre, S. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology, 2001, 25(4), 505-513.
137. Diaz-Cabiale, Z.; Vivo, M.; Del Arco, A.; O'Connor, W.T.; Harte, M.K.; Muller, C.E.; Martinez, E.; Popoli, P.; Fuxe, K.; Ferre, S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett., 2002, 324(2), 154-158.
138. Ferre, S.; Karcz-Kubicha, M.; Hope, B.T.; Popoli, P.; Burgueno, J.; Gutierrez, M.A.; Casado, V.; Fuxe, K.; Goldberg, S.R.; Lluis, C.; Franco, R.; Ciruela, F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA, 2002, 99(18), 11940-11945.
139. Fuxe, K.; Agnati, L.F.; Jacobsen, K.; Hillion, J.; Canals, M.; Torvinen, M.; Tinner-Staines, B.; Staines, W.; Rosin, D.; Terasmaa, A.; Popoli, P.; Leo, G.; Vergoni, V.; Lluis, C.; Ciruela, F.; Franco, R.; Ferre, S. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology, 2003, 61(11 Suppl 6), S19-S23.
140. Cabello, N.; Gandia, J.; Bertarelli, D.C.; Watanabe, M.; Lluis, C.; Franco, R.; Ferre, S.; Lujan, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J. Neurochem., 2009, 109(5), 1497-1507.
141. Kearney, J.A.; Becker, J.B.; Frey, K.A.; Albin, R.L. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience, 1998, 87(4), 881-891.
142. Kearney, J.A.; Frey, K.A.; Albin, R.L. Metabotropic glutamate agonist-induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study. J. Neurosci., 1997, 17(11), 4415-4425.
143. Wardas, J.; Pietraszek, M.; Wolfarth, S.; Ossowska, K. The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson's disease. Neuroscience, 2003, 122(3), 747-756.
144. Phillips, J.M.; Lam, H.A.; Ackerson, L.C.; Maidment, N.T. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci., 2006, 23(1), 151-160.
145. Armentero, M.T.; Fancellu, R.; Nappi, G.; Bramanti, P.; Blandini, F. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol. Dis., 2006, 22(1), 1-9.
146. Oueslati, A.; Breysse, N.; Amalric, M.; Kerkerian-Le Goff, L.; Salin, P. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur. J. Neurosci., 2005, 22(11), 2765-2774.
147. Pisani, A.; Bonsi, P.; Centonze, D.; Gubellini, P.; Bernardi, G.; Calabresi, P. Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology, 2003, 45(1), 45-56.
148. Samadi, P.; Gregoire, L.; Morissette, M.; Calon, F.; Hadj Tahar, A.; Dridi, M.; Belanger, N.; Meltzer, L.T.; Bedard, P.J.; Di Paolo, T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging, 2007, 29(7), 1040-1051.
149. Dekundy, A.; Pietraszek, M.; Schaefer, D.; Cenci, M.A.; Danysz, W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull., 2006, 69(3), 318-326.
150. Levandis, G.; Bazzini, E.; Armentero, M.T.; Nappi, G.; Blandini, F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol. Dis., 2008, 29(1), 161-168.
151. Mela, F.; Marti, M.; Dekundy, A.; Danysz, W.; Morari, M.; Cenci, M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem., 2007, 101(2), 483-497.
152. Rylander, D.; Recchia, A.; Mela, F.; Dekundy, A.; Danysz, W.; Cenci, A.M. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalling. J. Pharmacol. Exp. Ther., 2009, 330(1), 227-235.
153. Bradley, S.R.; Marino, M.J.; Wittmann, M.; Rouse, S.T.; Awad, H.; Levey,
154. Rouse, S.T.; Marino, M.J.; Bradley, S.R.; Awad, H.; Wittmann, M.; Conn, P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther., 2000, 88(3), 427-435.
155. Dawson, L.; Chadha, A.; Megalou, M.; Duty, S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br. J. Pharmacol., 2000, 129(3), 541-546.
156. Konieczny, J.; Ossowska, K.; Wolfarth, S.; Pilc, A. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn. Schmiedebergs. Arch. Pharmacol., 1998, 358(4), 500-502.
157. Murray, T.K.; Messenger, M.J.; Ward, M.A.; Woodhouse, S.; Osborne, D.J.; Duty, S.; O'Neill, M.J. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav., 2002, 73(2), 455-466.
158. Lovinger, D.M.; McCool, B.A. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J. Neurophysiol., 1995, 73(3), 1076-1083.
159. Picconi, B.; Pisani, A.; Centonze, D.; Battaglia, G.; Storto, M.; Nicoletti, F.; Bernardi, G.; Calabresi, P. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain, 2002, 125(Pt 12), 2635-2645.
160. Pisani, A.; Bonsi, P.; Catania, M.V.; Giuffrida, R.; Morari, M.; Marti, M.; Centonze, D.; Bernardi, G.; Kingston, A.E.; Calabresi, P. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J. Neurosci., 2002, 22(14), 6176-6185.
161. Bradley, S.R.; Standaert, D.G.; Levey, A.I.; Conn, P.J. Distribution of group III mGluRs in rat basal ganglia with subtype-specific antibodies. Ann. NY Acad. Sci., 1999, 868, 531-534.
162. Bradley, S.R.; Standaert, D.G.; Rhodes, K.J.; Rees, H.D.; Testa, C.M.; Levey, A.I.; Conn, P.J. Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. J. Comp. Neurol., 1999, 407(1), 33-46.
163. Matsui, T.; Kita, H. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus. Neuroscience, 2003, 122(3), 727-737.
164. Valenti, O.; Marino, M.J.; Wittmann, M.; Lis, E.; DiLella, A.G.; Kinney, G.G.; Conn, P.J. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci., 2003, 23(18), 7218-7226.
165. Wittmann, M.; Marino, M.J.; Bradley, S.R.; Conn, P.J. Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. J. Neurophysiol., 2001, 85(5), 1960-1968.
166. Macinnes, N.; Duty, S. Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo. Eur. J. Pharmacol., 2008, 580(1-2), 95-99.
167. MacInnes, N.; Messenger, M.J.; Duty, S. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br. J. Pharmacol., 2004, 141(1), 15-22.
168. Acher, F.C.; Tellier, F.J.; Azerad, R.; Brabet, I.N.; Fagni, L.; Pin, J.P. Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J. Med. Chem., 1997, 40(19), 3119-3129.
169. Lopez, S.; Turle-Lorenzo, N.; Acher, F.; De Leonibus, E.; Mele, A.; Amalric, M. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci., 2007, 27(25), 6701-6711.
170. Konieczny, J.; Wardas, J.; Kuter, K.; Pilc, A.; Ossowska, K. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience, 2007, 145(2), 611-620.
171. Sibille, P.; Lopez, S.; Brabet, I.; Valenti, O.; Oueslati, N.; Gaven, F.; Goudet, C.; Bertrand, H.O.; Neyton, J.; Marino, M.J.; Amalric, M.; Pin, J.P.; Acher, F.C. Synthesis and biological evaluation of 1-amino-2- phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J. Med. Chem., 2007, 50(15), 3585-3595.
172. Lopez, S.; Turle-Lorenzo, N.; Johnston, T.H.; Brotchie, J.M.; Schann, S.; Neuville, P.; Amalric, M. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology, 2008, 55(4), 483-490.
173. Maj, M.; Bruno, V.; Dragic, Z.; Yamamoto, R.; Battaglia, G.; Inderbitzin, W.; Stoehr, N.; Stein, T.; Gasparini, F.; Vranesic, I.; Kuhn, R.; Nicoletti, F.; Flor, P.J. (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology, 2003, 45(7), 895-906.
174. Marino, M.J.; Williams, D.L.; Jr.; O'Brien, J.A.; Valenti, O.; McDonald, T.P.; Clements, M.K.; Wang, R.; DiLella, A.G.; Hess, J.F.; Kinney, G.G.; Conn, P.J. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl. Acad. Sci. USA, 2003, 100(23), 13668-13673.
175. Battaglia, G.; Busceti, C.L.; Molinaro, G.; Biagioni, F.; Traficante, A.; Nicoletti, F.; Bruno, V. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci., 2006, 26(27), 7222-7229.
176. Niswender, C.M.; Johnson, K.A.; Weaver, C.D.; Jones, C.K.; Xiang, Z.; Luo, Q.; Rodriguez, A.L.; Marlo, J.E.; de Paulis, T.; Thompson, A.D.; Days, E.L.; Nalywajko, T.; Austin, C.A.; Williams, M.B.; Ayala, J.E.; Williams, R.; Lindsley, C.W.; Conn, P.J. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol., 2008, 74(5), 1345-1358.
177. Lavreysen, H.; Dautzenberg, F.M. Therapeutic potential of group III metabotropic glutamate receptors. Curr. Med. Chem., 2008, 15(7), 671-684.
178. Schneider, F.; Althaus, A.; Backes, V.; Dodel, R. Psychiatric symptoms in Parkinson's disease. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258(Suppl 5), 55-59.
179. De Leonibus, E.; Manago, F.; Giordani, F.; Petrosino, F.; Lopez, S.; Oliverio, A.; Amalric, M.; Mele, A. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology, 2009, 34(3), 729-738.
180. Palucha, A.; Pilc, A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther., 2007, 115(1), 116-147.
181. Witkin, J.M.; Marek, G.J.; Johnson, B.G.; Schoepp, D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets, 2007, 6(2), 87-100.
182. Rodriguez, M.C.; Obeso, J.A.; Olanow, C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol., 1998, 44(3 Suppl 1), S175-S188.
183. Srivastava, R.; Brouillet, E.; Beal, M.F.; Storey, E.; Hyman, B.T. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol. Aging, 1993, 14(4), 295-301.
184. Turski, L.; Bressler, K.; Rettig, K.J.; Loschmann, P.A.; Wachtel, H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 1991, 349(6308), 414-418.
185. Chan, P.; Langston, J.W.; Di Monte, D.A. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. J. Pharmacol. Exp. Ther., 1993, 267(3), 1515-1520.
186. Lange, K.W.; Loschmann, P.A.; Sofic, E.; Burg, M.; Horowski, R.; Kalveram, K.T.; Wachtel, H.; Riederer, P. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn. Schmiedebergs. Arch. Pharmacol., 1993, 348(6), 586-592.
187. Zuddas, A.; Oberto, G.; Vaglini, F.; Fascetti, F.; Fornai, F.; Corsini, G.U. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J. Neurochem., 1992, 59(2), 733-739.
188. Chan, P.; Di Monte, D.A.; Langston, J.W.; Janson, A.M. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J. Pharmacol. Exp. Ther., 1997, 280(1), 439-446.
189. Sonsalla, P.K.; Zeevalk, G.D.; Manzino, L.; Giovanni, A.; Nicklas, W.J. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J. Neurochem., 1992, 58(5), 1979-1982.
190. Leaver, K.R.; Allbutt, H.N.; Creber, N.J.; Kassiou, M.; Henderson, J.M. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clin. Exp. Pharmacol. Physiol., 2008, 35(11), 1388-1394.
191. Black, M.D. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits: a review of preclinical data. Psychopharmacology (Berl.), 2005, 179(1), 154-163.
192. O'Neill, M.J.; Murray, T.K.; Clay, M.P.; Lindstrom, T.; Yang, C.R.; Nisenbaum, E.S. LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. CNS Drug Rev., 2005, 11(1), 77-96.
193. O'Neill, M.J.; Murray, T.K.; Whalley, K.; Ward, M.A.; Hicks, C.A.; Woodhouse, S.; Osborne, D.J.; Skolnick, P. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur. J. Pharmacol., 2004, 486(2), 163-174.
194. Murray, T.K.; Whalley, K.; Robinson, C.S.; Ward, M.A.; Hicks, C.A.; Lodge, D.; Vandergriff, J.L.; Baumbarger, P.; Siuda, E.; Gates, M.; Ogden, A.M.; Skolnick, P.; Zimmerman, D.M.; Nisenbaum, E.S.; Bleakman, D.; O'Neill, M.J. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther., 2003, 306(2), 752-762.
195. Bloss, E.B.; Hunter, R.G.; Waters, E.M.; Munoz, C.; Bernard, K.; McEwen, B.S. Behavioral and biological effects of chronic S18986, a positive AMPA receptor modulator, during aging. Exp. Neurol., 2008, 210(1), 109-117.
196. Blandini, F.; Greenamyre, J.T.; Fancellu, R.; Nappi, G. Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurol. Sci., 2001, 22(1), 49-50.
197. Blandini, F.; Nappi, G.; Greenamyre, J.T. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann. Neurol., 2001, 49(4), 525-529.
198. Battaglia, G.; Busceti, C.L.; Molinaro, G.; Biagioni, F.; Storto, M.; Fornai, F.; Nicoletti, F.; Bruno, V. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci., 2004, 24(4), 828-835.
199. Aguirre, J.A.; Kehr, J.; Yoshitake, T.; Liu, F.L.; Rivera, A.; Fernandez-Espinola, S.; Andbjer, B.; Leo, G.; Medhurst, A.D.; Agnati, L.F.; Fuxe, K. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res., 2005, 1033(2), 216-220.
200. Battaglia, G.; Fornai, F.; Busceti, C.L.; Aloisi, G.; Cerrito, F.; De Blasi, A.; Melchiorri, D.; Nicoletti, F. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci., 2002, 22(6), 2135-2141.
201. Vernon, A.C.; Palmer, S.; Datla, K.P.; Zbarsky, V.; Croucher, M.J.; Dexter, D.T. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci., 2005, 22(7), 1799-1806.
202. Vernon, A.C.; Zbarsky, V.; Datla, K.P.; Croucher, M.J.; Dexter, D.T. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J. Neurochem., 2007, 103(3), 1075-1091.
203. Prisco, S.; Natoli, S.; Bernardi, G.; Mercuri, N.B. Group I metabotropic glutamate receptors activate burst firing in rat midbrain dopaminergic neurons. Neuropharmacology, 2002, 42(3), 289-296.
204. Wang, L.; Kitai, S.T.; Xiang, Z. Modulation of excitatory synaptic transmission by endogenous glutamate acting on presynaptic group II mGluRs in rat substantia nigra compacta. J. Neurosci. Res., 2005, 82(6), 778-787.
205. Wigmore, M.A.; Lacey, M.G. Metabotropic glutamate receptors depress glutamate-mediated synaptic input to rat midbrain dopamine neurones in vitro. Br. J. Pharmacol., 1998, 123(4), 667-674.
206. Battaglia, G.; Busceti, C.L.; Pontarelli, F.; Biagioni, F.; Fornai, F.; Paparelli, A.; Bruno, V.; Ruggieri, S.; Nicoletti, F. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology, 2003, 45(2), 155-166.
207. Matarredona, E.R.; Santiago, M.; Venero, J.L.; Cano, J.; Machado, A. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J. Neurochem., 2001, 76(2), 351-360.
208. Venero, J.L.; Santiago, M.; Tomas-Camardiel, M.; Matarredona, E.R.; Cano, J.; Machado, A. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum: correlation with neuronal injury. Neuroscience, 2002, 113(4), 857-869.
209. Bruno, V.; Battaglia, G.; Casabona, G.; Copani, A.; Caciagli, F.; Nicoletti, F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci., 1998, 18(23), 9594-9600.
210. Bruno, V.; Sureda, F.X.; Storto, M.; Casabona, G.; Caruso, A.; Knopfel, T.; Kuhn, R.; Nicoletti, F. The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J. Neurosci., 1997, 17(6), 1891-1897.
211. D'Onofrio, M.; Cuomo, L.; Battaglia, G.; Ngomba, R.T.; Storto, M.; Kingston, A.E.; Orzi, F.; De Blasi, A.; Di Iorio, P.; Nicoletti, F.; Bruno, V. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem., 2001, 78(3), 435-445.
212. Corti, C.; Battaglia, G.; Molinaro, G.; Riozzi, B.; Pittaluga, A.; Corsi, M.; Mugnaini, M.; Nicoletti, F.; Bruno, V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci., 2007, 27(31), 8297-8308.
213. Valenti, O.; Conn, P.J.; Marino, M.J. Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. J. Cell Physiol., 2002, 191(2), 125-137.
214. Valenti, O.; Mannaioni, G.; Seabrook, G.R.; Conn, P.J.; Marino, M.J. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol. Exp. Ther., 2005, 313(3), 1296-1304.
215. Bruno, V.; Battaglia, G.; Ksiazek, I.; van der Putten, H.; Catania, M.V.; Giuffrida, R.; Lukic, S.; Leonhardt, T.; Inderbitzin, W.; Gasparini, F.; Kuhn, R.; Hampson, D.R.; Nicoletti, F.; Flor, P.J. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci., 2000, 20(17), 6413-6420.
216. Flor, P.J.; Battaglia, G.; Nicoletti, F.; Gasparini, F.; Bruno, V. Neuroprotective activity of metabotropic glutamate receptor ligands. Adv. Exp. Med. Biol., 2002, 513, 197-223.
217. Gasparini, F.; Bruno, V.; Battaglia, G.; Lukic, S.; Leonhardt, T.; Inderbitzin, W.; Laurie, D.; Sommer, B.; Varney, M.A.; Hess, S.D.; Johnson, E.C.; Kuhn, R.; Urwyler, S.; Sauer, D.; Portet, C.; Schmutz, M.; Nicoletti, F.; Flor, P.J. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J. Pharmacol. Exp. Ther., 1999, 289(3), 1678-1687.
218. Besong, G.; Battaglia, G.; D'Onofrio, M.; Di Marco, R.; Ngomba, R.T.; Storto, M.; Castiglione, M.; Mangano, K.; Busceti, C.L.; Nicoletti, F.R.; Bacon, K.; Tusche, M.; Valenti, O.; Conn, P.J.; Bruno, V.; Nicoletti, F. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J. Neurosci., 2002, 22(13), 5403-5411.
219. Rentzos, M.; Nikolaou, C.; Andreadou, E.; Paraskevas, G.P.; Rombos, A.; Zoga, M.; Tsoutsou, A.; Boufidou, F.; Kapaki, E.; Vassilopoulos, D. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol. Scand., 2007, 116(6), 374-379.
220. Vernon, A.C.; Zbarsky, V.; Datla, K.P.; Dexter, D.T.; Croucher, M.J. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J. Pharmacol. Exp. Ther., 2007, 320(1), 397-409.
221. Vernon, A.C.; Croucher, M.J.; Dexter, D.T. Additive neuroprotection by metabotropic glutamate receptor subtypeselective ligands in a rat Parkinson's model. Neuroreport, 2008, 19(4), 475-478.